Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 2/2020

17.02.2020 | Prolactinoma

Radiation techniques in aggressive pituitary tumours and carcinomas

verfasst von: Frederic Castinetti

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Defining the role of radiation techniques in treatment of aggressive pituitary tumours and carcinomas is a difficult task: indeed, studies reported in the literature on this topic can probably be counted on the fingers of one hand. To try to better define these roles, it is thus necessary to extrapolate based on anti-secretory and anti-tumor efficacy reported in studies on non-selected pituitary tumours, regardless of their pathological status and intrinsic aggressiveness. Generally, radiation techniques are delivered as part of a multimodal treatment, usually with the primary aim of controlling tumor volume. Side-effects need to be divided into short and long-term, also depending on the overall prognosis of the tumour, since hypopituitarism will likely appear in the majority of patients, extra-pituitary side-effects, which have been reported after a significant delay after the procedure, can only be considered in patients with less aggressive pituitary tumours. In this review, we will first detail the different modalities of radiation techniques and the inherent limits of each technique depending on the volume and the localization of the tumour. We will then discuss the anti-tumour and anti-secretory efficacy of radiation techniques in aggressive pituitary tumors, either as a single treatment or as part of a multimodal treatment. Finally we will discuss the technique-specific side-effects.
Literatur
1.
Zurück zum Zitat Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018 Jan;178(1):G1–24.CrossRef Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018 Jan;178(1):G1–24.CrossRef
2.
Zurück zum Zitat McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265–76.CrossRef McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265–76.CrossRef
3.
Zurück zum Zitat Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol. 2017 May;176(5):645–55.CrossRef Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol. 2017 May;176(5):645–55.CrossRef
4.
Zurück zum Zitat Vance ML. Pituitary radiotherapy. Endocrinol Metab Clin N Am. 2005 Jun;34(2):479–87 xi. Vance ML. Pituitary radiotherapy. Endocrinol Metab Clin N Am. 2005 Jun;34(2):479–87 xi.
5.
Zurück zum Zitat Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord. 2009 Jun;10(2):135–44.CrossRef Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord. 2009 Jun;10(2):135–44.CrossRef
6.
Zurück zum Zitat Minniti G, Flickinger J. The risk/benefit ratio of radiotherapy in pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;16:101269.CrossRef Minniti G, Flickinger J. The risk/benefit ratio of radiotherapy in pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;16:101269.CrossRef
7.
Zurück zum Zitat Chanson P, Dormoy A, Dekkers O. Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol. 2019 May;1. Chanson P, Dormoy A, Dekkers O. Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol. 2019 May;1.
8.
Zurück zum Zitat Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, et al. Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg. 2013;119(2):446–56.CrossRef Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, et al. Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg. 2013;119(2):446–56.CrossRef
9.
Zurück zum Zitat Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol. 1998;48(3):331–7.CrossRef Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol. 1998;48(3):331–7.CrossRef
10.
Zurück zum Zitat Minniti G, Scaringi C, Poggi M, Jaffrain Rea ML, Trillò G, Esposito V, et al. Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol. 2015;172(4):433–41.CrossRef Minniti G, Scaringi C, Poggi M, Jaffrain Rea ML, Trillò G, Esposito V, et al. Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol. 2015;172(4):433–41.CrossRef
11.
Zurück zum Zitat Ogawa Y, Jokura H, Niizuma K, Tominaga T. Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant? J Neuro-Oncol. 2018 May;137(3):543–9.CrossRef Ogawa Y, Jokura H, Niizuma K, Tominaga T. Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant? J Neuro-Oncol. 2018 May;137(3):543–9.CrossRef
12.
Zurück zum Zitat Pomeraniec IJ, Dallapiazza RF, Xu Z, Jane JA, Sheehan JP. Early versus late gamma knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. J Neurosurg. 2016;125(1):202–12.CrossRef Pomeraniec IJ, Dallapiazza RF, Xu Z, Jane JA, Sheehan JP. Early versus late gamma knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. J Neurosurg. 2016;125(1):202–12.CrossRef
13.
Zurück zum Zitat Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S, et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):239–47.CrossRef Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S, et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):239–47.CrossRef
14.
Zurück zum Zitat Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, et al. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. J Clin Endocrinol Metab. 2017;102(9):3368–74.CrossRef Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, et al. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. J Clin Endocrinol Metab. 2017;102(9):3368–74.CrossRef
15.
Zurück zum Zitat Verma J, McCutcheon IE, Waguespack SG, Mahajan A. Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas. Pituitary. 2014 Dec;17(6):539–45.CrossRef Verma J, McCutcheon IE, Waguespack SG, Mahajan A. Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas. Pituitary. 2014 Dec;17(6):539–45.CrossRef
16.
Zurück zum Zitat Castinetti F, Régis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol. 2010 Apr;6(4):214–23.CrossRef Castinetti F, Régis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol. 2010 Apr;6(4):214–23.CrossRef
17.
Zurück zum Zitat Ding D, Mehta GU, Patibandla MR, Lee C-C, Liscak R, Kano H, et al. Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study. Neurosurgery. 2019 Mar 1;84(3):717–25.CrossRef Ding D, Mehta GU, Patibandla MR, Lee C-C, Liscak R, Kano H, et al. Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study. Neurosurgery. 2019 Mar 1;84(3):717–25.CrossRef
18.
Zurück zum Zitat Mehta GU, Ding D, Patibandla MR, Kano H, Sisterson N, Su Y-H, et al. Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study. J Clin Endocrinol Metab. 2017;102(11):4284–91.CrossRef Mehta GU, Ding D, Patibandla MR, Kano H, Sisterson N, Su Y-H, et al. Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study. J Clin Endocrinol Metab. 2017;102(11):4284–91.CrossRef
19.
Zurück zum Zitat Hung Y-C, Lee C-C, Yang H-C, Mohammed N, Kearns KN, Nabeel AM, et al. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study. J Neurosurg. 2019 Aug;2:1–10. Hung Y-C, Lee C-C, Yang H-C, Mohammed N, Kearns KN, Nabeel AM, et al. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study. J Neurosurg. 2019 Aug;2:1–10.
20.
Zurück zum Zitat Shimon I, Jallad RS, Fleseriu M, Yedinak CG, Greenman Y, Bronstein MD. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. Eur J Endocrinol. 2015;172(6):707–13.CrossRef Shimon I, Jallad RS, Fleseriu M, Yedinak CG, Greenman Y, Bronstein MD. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. Eur J Endocrinol. 2015;172(6):707–13.CrossRef
21.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRef Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRef
22.
Zurück zum Zitat Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res. 2008;14(3):931–8.CrossRef Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res. 2008;14(3):931–8.CrossRef
23.
Zurück zum Zitat Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009;75(1):212–9.CrossRef Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009;75(1):212–9.CrossRef
24.
Zurück zum Zitat Ilie MD, Lasolle H, Raverot G. Emerging and novel treatments for pituitary tumors. J Clin Med. 2019;25:8(8). Ilie MD, Lasolle H, Raverot G. Emerging and novel treatments for pituitary tumors. J Clin Med. 2019;25:8(8).
25.
Zurück zum Zitat Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci. 2017;41:75–7.CrossRef Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci. 2017;41:75–7.CrossRef
26.
Zurück zum Zitat Dutta P, Reddy KS, Rai A, Madugundu AK, Solanki HS, Bhansali A, et al. Surgery, Octreotide, Temozolomide, Bevacizumab, radiotherapy, and Pegvisomant treatment of an AIP mutation–positive child. J Clin Endocrinol Metab. 2019;104(8):3539–44.CrossRef Dutta P, Reddy KS, Rai A, Madugundu AK, Solanki HS, Bhansali A, et al. Surgery, Octreotide, Temozolomide, Bevacizumab, radiotherapy, and Pegvisomant treatment of an AIP mutation–positive child. J Clin Endocrinol Metab. 2019;104(8):3539–44.CrossRef
27.
Zurück zum Zitat Cordeiro D, Xu Z, Mehta G, Ding D, Vance ML, Kano H, et al. Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: a multicenter, international study. J Neurosurg. 2018;09. Cordeiro D, Xu Z, Mehta G, Ding D, Vance ML, Kano H, et al. Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: a multicenter, international study. J Neurosurg. 2018;09.
28.
Zurück zum Zitat Burman P, van Beek AP, Biller BMK, Camacho-Hübner C, Mattsson AF. Radiotherapy, especially at Young age, increases the risk for De novo brain tumors in patients treated for pituitary/Sellar lesions. J Clin Endocrinol Metab. 2017;102(3):1051–8.PubMed Burman P, van Beek AP, Biller BMK, Camacho-Hübner C, Mattsson AF. Radiotherapy, especially at Young age, increases the risk for De novo brain tumors in patients treated for pituitary/Sellar lesions. J Clin Endocrinol Metab. 2017;102(3):1051–8.PubMed
Metadaten
Titel
Radiation techniques in aggressive pituitary tumours and carcinomas
verfasst von
Frederic Castinetti
Publikationsdatum
17.02.2020
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2020
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09543-y

Weitere Artikel der Ausgabe 2/2020

Reviews in Endocrine and Metabolic Disorders 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.